Asciminib has the potential to succeed where other TKIs have failed in CML

Tyrosine kinase inhibitors (TKIs) are some of the most successful drugs available for the treatment of a myriad hematological cancers. However, they are not perfect, as patients can relapse or develop... Author: VJHemOnc Added: 08/15/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts